Claims for Patent: 5,328,930

Summary for Patent: 5,328,930

Title:	Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
Abstract:	Methods for the treatment of Microsporidia keratoconjunctivitis and Acanthamoeba keratitis are disclosed that include the topical administration of an effective amount of fumagillin or a derivative or pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier or diluent.
Inventor(s):	Wilson; Louis A. (Marietta, GA)
Assignee:	Emory University (Atlanta, GA)
Application Number:	08/024,718
Patent Claims:	1. A method for the treatment of microsporidial keratoconjunctivitis that includes the topical administration of an effective amount of a compound of the formula: ##STR3## wherein R is hydrogen; alkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; and R' is hydrogen; alkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; or C(O)R" wherein R" is straight, branched, or cyclic C.sub.1 to C.sub.10 alkyl, alkoxyalkyl, aralkyl including benzyl, aryloxyalkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; sulfonate ester, the mono, di or triphosphate ester, trityl or monomethoxytrityl; trialkylsilyl, or diphenylmethylsilyl. 2. The method of claim 1, wherein the microsporidia keratoconjunctivitis is caused by E. cuniculi. 3. The method of claim 1, wherein the microsporidia keratoconjunctivitis is caused by E. hellem. 4. The method of claim 1, wherein the microsporidial keratoconjunctivitis is caused by Nosema sp. 5. The method of claim 1, wherein R is H and R' is methyl. 6. The method of claim 1, wherein the compound is administered as a pharmaceutically acceptable salt. 7. The method of claim 6, wherein the salt is the bicyclohexyl ammonium salt of the compound. 8. The method of claim 1, wherein the compound is administered in a dosage concentration of between 50 .mu.g/ml and 10 mg/ml. 9. The method of claim 1, wherein the compound is administered between once and four times daily. 10. A method for the treatment of Acanthamoeba keratoconjunctivitis that includes the topical administration of an effective amount of a compound of the formula: ##STR4## wherein R is hydrogen; alkyl; phenyl or benzyl optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; and R' is hydrogen; alkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; or C(O)R" wherein R" is straight, branched, or cyclic C.sub.1 to C.sub.10 alkyl, alkoxyalkyl, aralkyl including benzyl, aryloxyalkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; sulfonate ester, the mono, di or triphosphate ester, trityl or monomethoxytrityl; trialkylsilyl, or diphenylmethylsilyl. 11. The method of claim 10, wherein R is H and R' is methyl. 12. The method of claim 10, wherein the compound is administered as a pharmaceutically acceptable salt. 13. The method of claim 12, wherein the salt is the bicyclohexyl ammonium salt of the compound. 14. The method of claim 10, wherein the compound is administered in a dosage concentration of between 50 .mu.g/ml and 10 mg/ml. 15. The method of claim 10, wherein the compound is administered between once and four times daily. 16. A topical composition for the treatment of Microsporidial Keratoconjunctivitis or Acanthamoeba Keratitis that includes an effective amount of a compound of the formula: ##STR5## wherein R is hydrogen; alkyl; phenyl or benzyl optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; and R' is hydrogen; alkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; or C(O)R" wherein R" is straight, branched, or cyclic C.sub.1 to C.sub.10 alkyl, alkoxyalkyl, aralkyl including benzyl, aryloxyalkyl; phenyl or benzyl, optionally substituted with halogen, C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy, or a mixture thereof; sulfonate ester, the mono, di or triphosphate ester, trityl or monomethoxytrityl; trialkylsilyl, or diphenylmethylsilyl; or its pharmaceutically acceptable salt, in a pharmaceutically acceptable carrier or diluent. 17. The composition of claim 16, wherein the composition includes between approximately 50 .mu.g/ml and 10 mg/ml of active compound. 18. The composition of claim 16, wherein the composition is in the form of a solution. 19. The composition of claim 16, wherein the composition is in the form of a suspension. 20. The composition of claim 16, wherein the composition is in the form of an ointment. 21. The composition of claim 16, wherein the composition comprises a material selected from the group consisting of sterile water, saline or phosphate buffered saline, fixed oils, polyethylene glycols, glycerine, polyvinyl alcohol, polysorbate, mineral oil, corn oil, petrolatum, lanolin alcohol, white petrolatum, cetyl alcohol, glyceryl monostearate, polyoxyl 40 stearate and propylene glycol. 22. The composition of claim 16, wherein the compound is in the form of a pharmaceutically acceptable salt. 23. The composition of claim 22, wherein the salt is water soluble. 24. The composition of claim 23, wherein the compound is in the form of a bicyclohexyl ammonium salt.

Details for Patent 5,328,930

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23